[go: up one dir, main page]

CL2019003843A1 - Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas. - Google Patents

Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas.

Info

Publication number
CL2019003843A1
CL2019003843A1 CL2019003843A CL2019003843A CL2019003843A1 CL 2019003843 A1 CL2019003843 A1 CL 2019003843A1 CL 2019003843 A CL2019003843 A CL 2019003843A CL 2019003843 A CL2019003843 A CL 2019003843A CL 2019003843 A1 CL2019003843 A1 CL 2019003843A1
Authority
CL
Chile
Prior art keywords
protein
recombinant viral
human cells
genetic material
viral particles
Prior art date
Application number
CL2019003843A
Other languages
English (en)
Inventor
Andrew J Murphy
Christos Kyratsous
Christopher Schoenherr
Leah Sabin
Aris N Economides
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63080488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019003843(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2019003843A1 publication Critical patent/CL2019003843A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

EN LA PRESENTE DESCRIPCIÓN SE PROPORCIONAN COMPOSICIONES Y MÉTODOS PARA REORIENTAR PARTÍCULAS DE CÁPSIDAS VIRALES RECOMBINANTES A TRAVÉS DE UN PAR DE UNIÓN PROTEÍNA:PROTEÍNA ESPECÍFICO QUE FORMA UN ENLACE COVALENTE, POR EJEMPLO, ISOPEPTÍDICO, PARA MOSTRAR UN LIGANDO DE ORIENTACIÓN SOBRE LA PROTEÍNA DE CÁPSIDA, EN DONDE EL LIGANDO DE ORIENTACIÓN SE UNE ESPECÍFICAMENTE A UN MARCADOR DE SUPERFICIE CELULAR EXPRESADO EN LA CÉLULA DE INTERÉS.
CL2019003843A 2017-06-27 2019-12-26 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas. CL2019003843A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762525708P 2017-06-27 2017-06-27

Publications (1)

Publication Number Publication Date
CL2019003843A1 true CL2019003843A1 (es) 2020-07-24

Family

ID=63080488

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019003843A CL2019003843A1 (es) 2017-06-27 2019-12-26 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas.
CL2020003438A CL2020003438A1 (es) 2017-06-27 2020-12-30 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas (divisional de la solicitud no. 201903843)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020003438A CL2020003438A1 (es) 2017-06-27 2020-12-30 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas (divisional de la solicitud no. 201903843)

Country Status (30)

Country Link
US (1) US20200140492A1 (es)
EP (2) EP4219529A1 (es)
JP (4) JP2020525020A (es)
KR (2) KR20250091321A (es)
CN (2) CN116891534A (es)
AU (2) AU2018290885B2 (es)
BR (1) BR112019027866A2 (es)
CA (1) CA3066950A1 (es)
CL (2) CL2019003843A1 (es)
CO (1) CO2019014684A2 (es)
CY (1) CY1126149T1 (es)
DK (1) DK3645553T5 (es)
ES (1) ES2943020T3 (es)
FI (1) FI3645553T3 (es)
HR (1) HRP20230538T1 (es)
HU (1) HUE061908T2 (es)
IL (2) IL318395A (es)
LT (1) LT3645553T (es)
MA (1) MA49514B1 (es)
MD (1) MD3645553T2 (es)
MX (2) MX2020000246A (es)
PE (2) PE20200895A1 (es)
PH (1) PH12019550269B1 (es)
PL (1) PL3645553T3 (es)
PT (1) PT3645553T (es)
RS (1) RS64233B1 (es)
SG (1) SG11201911614XA (es)
SI (1) SI3645553T1 (es)
SM (1) SMT202300168T1 (es)
WO (1) WO2019006046A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
CN112041451B (zh) * 2018-02-28 2024-03-08 匹兹堡大学联邦系统高等教育 基于aav的基因和蛋白质递送模块化系统
CN111954683A (zh) 2018-04-05 2020-11-17 生物辐射Abd瑟罗泰克有限公司 感兴趣的蛋白质的展示系统
GB201903479D0 (en) * 2019-03-14 2019-05-01 Univ Oxford Innovation Ltd Polypeptide with enchanced rate of spontaneous isopeptide bond formation with it's peptide tag partner and uses thereof
WO2020188350A1 (en) * 2019-03-18 2020-09-24 Bio-Rad Abd Serotec Gmbh Protection of spytag-containing periplasmic fusion proteins from protease tsp and ompt degradation
MA56035A (fr) * 2019-05-24 2022-04-06 Regeneron Pharma Particules virales modifiées et leurs utilisations
EP3983117A4 (en) * 2019-06-11 2023-06-21 Chevron U.S.A. Inc. MEMBRANES FOR REMOVAL OF POLLUTION FROM NATURAL GAS AND METHODS OF USE THEREOF
BR112021026309A2 (pt) * 2019-06-26 2022-06-07 Ap Biosciences Inc Anticorpos para ativação de células t
GB201915905D0 (en) * 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
US20230002451A1 (en) * 2019-11-08 2023-01-05 President And Fellows Of Harvard College Viral capsid polypeptides
CN114632148B (zh) * 2020-12-15 2024-08-09 榕森生物科技(北京)有限公司 病原样抗原疫苗及其制备方法
CN114634578B (zh) * 2020-12-15 2024-04-02 榕森生物科技(北京)有限公司 针对新型冠状病毒感染的疫苗组合物
PE20241212A1 (es) 2021-11-04 2024-06-06 Regeneron Pharma Particulas virales redirigidas a musculo esqueletico
CN114213505B (zh) * 2021-12-10 2022-09-20 和元生物技术（上海）股份有限公司 一种适用于特异感染u87-mg细胞的腺相关病毒突变体
CA3256953A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. VECTORS AND METHODS FOR IN VIVO ANTIBODY PRODUCTION
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
IL318636A (en) 2022-07-29 2025-03-01 Regeneron Pharma Viral particles retargeted to transferrin receptor 1
EP4619438A2 (en) 2022-11-14 2025-09-24 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
TW202434886A (zh) 2022-11-18 2024-09-01 美商再生元醫藥公司 用於偵測及評估病毒及類病毒顆粒的方法
WO2024124019A2 (en) * 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
KR20250150011A (ko) 2023-02-13 2025-10-17 리제너론 파마슈티칼스 인코포레이티드 항-인간 cacng1 항체를 이용한 근육 관련 장애 치료
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
US20240425825A1 (en) 2023-06-20 2024-12-26 Regeneron Pharmaceuticals, Inc. Methods for purifying filled adeno-associated virus capsids
WO2025018388A1 (ja) * 2023-07-20 2025-01-23 学校法人自治医科大学 抗菌カプシド、治療用組成物、殺菌剤、細菌除去方法、殺菌方法、動物治療方法、遺伝子導入方法、細菌機能追加方法、抗菌カプシドの製造方法、抗菌カプシドの標識方法、及び抗菌カプシドの細胞内送達方法
CN119552829A (zh) * 2023-09-01 2025-03-04 北京昌平实验室 靶向性基因编辑酶工程化的腺相关病毒及其药物组合物
US20250122482A1 (en) 2023-09-07 2025-04-17 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
WO2025097030A1 (en) * 2023-11-02 2025-05-08 Oregon State University Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus
WO2025151796A1 (en) 2024-01-11 2025-07-17 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to nervous system tissues
WO2025155923A1 (en) 2024-01-17 2025-07-24 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025217174A1 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv
WO2025217163A2 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Novel aav capsids binding to human cd59
CN119529113A (zh) * 2024-11-28 2025-02-28 浙江大学 一种基于PCV2 VLPs的纳米抗原展示平台及制备方法和应用
CN120519522B (zh) * 2025-07-23 2025-11-18 南昌大学第一附属医院 基于双向负载模块的通用工程外泌体构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286981C (zh) 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
CN102711449B (zh) 2009-12-10 2015-01-07 瑞泽恩制药公司 生产重链抗体的小鼠
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
AR094403A1 (es) * 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
US20160018835A1 (en) * 2014-07-18 2016-01-21 Retroficiency, Inc. System and method for virtual energy assessment of facilities
DE16703049T1 (de) * 2015-01-15 2018-07-12 University Of Copenhagen Virusähnliche partikel mit effizienter epitopanzeige
AU2016223379B2 (en) 2015-02-26 2019-11-14 Var2 Pharmaceuticals Aps Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (CARs) and immunotherapeutic targeting of cancer using CARs with split-protein binding systems
EP3141600A1 (en) 2015-09-11 2017-03-15 Institut National de la Recherche Agronomique Nepovirus coat protein fusion polypeptides and their use
IL315358A (en) * 2016-08-18 2024-11-01 Univ California CRISPR-CAS genome engineering using a modular AAV delivery system
CN112041451B (zh) * 2018-02-28 2024-03-08 匹兹堡大学联邦系统高等教育 基于aav的基因和蛋白质递送模块化系统

Also Published As

Publication number Publication date
EP3645553B1 (en) 2023-03-15
JP2024071769A (ja) 2024-05-24
DK3645553T3 (da) 2023-05-22
PT3645553T (pt) 2023-05-08
LT3645553T (lt) 2023-04-25
CN110997699A (zh) 2020-04-10
PH12019550269A1 (en) 2021-01-11
AU2018290885B2 (en) 2023-07-27
EP4219529A1 (en) 2023-08-02
CA3066950A1 (en) 2019-01-03
SMT202300168T1 (it) 2023-07-20
WO2019006046A2 (en) 2019-01-03
IL318395A (en) 2025-03-01
JP2025129257A (ja) 2025-09-04
CL2020003438A1 (es) 2021-07-23
EP3645553A2 (en) 2020-05-06
CN116891534A (zh) 2023-10-17
RU2020101596A3 (es) 2022-03-22
PL3645553T3 (pl) 2023-07-17
SG11201911614XA (en) 2020-01-30
AU2018290885A1 (en) 2020-01-16
AU2023204611B2 (en) 2025-10-30
FI3645553T3 (fi) 2023-05-22
WO2019006046A3 (en) 2019-02-14
US20200140492A1 (en) 2020-05-07
KR20200021987A (ko) 2020-03-02
MX2023009051A (es) 2023-08-10
BR112019027866A2 (pt) 2020-07-07
IL271570A (en) 2020-02-27
CY1126149T1 (el) 2023-11-15
PH12019550269B1 (en) 2024-05-22
MD3645553T2 (ro) 2023-07-31
JP2020525020A (ja) 2020-08-27
KR20250091321A (ko) 2025-06-20
PE20251541A1 (es) 2025-06-05
DK3645553T5 (da) 2024-08-26
MA49514B1 (fr) 2023-06-28
PE20200895A1 (es) 2020-09-08
RU2020101596A (ru) 2021-07-27
HRP20230538T1 (hr) 2023-08-04
ES2943020T3 (es) 2023-06-08
JP2022186991A (ja) 2022-12-15
MA49514A (fr) 2020-05-06
RS64233B1 (sr) 2023-06-30
MX2020000246A (es) 2020-08-10
CO2019014684A2 (es) 2020-01-17
SI3645553T1 (sl) 2023-06-30
AU2023204611A1 (en) 2023-08-03
HUE061908T2 (hu) 2023-09-28

Similar Documents

Publication Publication Date Title
CL2019003843A1 (es) Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas.
CL2019003842A1 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas.
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MY196882A (en) Recombinant binding proteins and their use
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
MX378807B (es) Inmunotoxinas de union a cd20 para inducir internalizacion celular y metodos que usan las mismas.
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
AR095437A1 (es) Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
AR099288A1 (es) Proteínas de fusión de interleucina-10
MX2016015944A (es) Metodos para cosechar cultivos de celulas de mamifero.
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2017012616A (es) Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y metodos para usar los mismos.
MX379210B (es) Acoplador trifuncional de antígeno de células t y métodos y usos del mismo.
GT201400302A (es) Celulas para producir iduronato-2-sulfatasa recombinante
EA201791918A1 (ru) Модификация белков клеток-хозяев
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
AU2016335217A8 (en) Antigen receptors and uses thereof
CY1121795T1 (el) Αντισωματα κατα toy cd52
MX2018009389A (es) Polipeptidos de union a la proteina a, anticuerpos anti-epha2 y metodos de uso de estos.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
NZ752275A (en) Compositions and methods for enhancing the stability of transgenes in poxviruses
MX2024002130A (es) Metodos y composiciones para mejorar la expresion de proteinas recombinantes.